Back to Search
Start Over
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
- Source :
-
Proceedings of the National Academy of Sciences of the United States of America . 3/3/2009, Vol. 106 Issue 9, p3342-3347. 6p. 4 Graphs. - Publication Year :
- 2009
-
Abstract
- All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear. From April 2001, we have followed 85 patients administrated ATRA/ATO with a median follow-up of 70 months. Eighty patients (94.1%) entered complete remission (CR). Kaplan-Meier estimates of the 5-year event-free survival (EFS) and overall survival (OS) for all patients were 89.2% ± 3.4% and 91.7% ± 3.0%, respectively, and the 5-year relapse-free survival (RFS) and OS for patients who achieved CR (n = 80) were 94.8% ± 2.5% and 97.4% ± 1.8%, respectively. Upon ATRA/ATO, prognosis was not influenced by initial white blood cell count, distinct PML-RARĪ± types, or FLT3 mutations. The toxicity profile was mild and revers- ible. No secondary carcinoma was observed, and 24 months after the last dose of ATRA/ATO, patients had urine arsenic concentrations well below the safety limit. These results demonstrate the high efficacy and minimal toxicity of ATRA/ATO treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for de novo APL. [ABSTRACT FROM AUTHOR]
- Subjects :
- *TRETINOIN
*ARSENIC
*LEUKEMIA
*PROGNOSIS
*CANCER patients
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 00278424
- Volume :
- 106
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Proceedings of the National Academy of Sciences of the United States of America
- Publication Type :
- Academic Journal
- Accession number :
- 37041037
- Full Text :
- https://doi.org/10.1073/pnas.0813280106